Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation reports news on its MRI-compatible medical-device business, including non-magnetic IV infusion pump systems, patient vital signs monitoring systems, accessories, disposables and related services sold to hospitals and acute care facilities. Company updates often describe financial results, revenue and earnings guidance, cash generation, and regular or special cash dividends.
IRMD news also covers product activity for systems such as the 3880 MRI-compatible patient vital signs monitor and the next-generation 3870 MRI-compatible IV infusion pump, along with investor conference participation and recognition tied to growth and financial performance.
IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its 2022 Q2 financial results on July 29, 2022, before the market opens. Management will hold a conference call at 11:00 a.m. ET the same day to discuss the results and answer questions. The call will be available online, and a recording will be accessible later on the company's website. IRADIMED is recognized for its innovative MRI-compatible medical devices, including the MRidium® IV infusion pump and 3880 vital signs monitoring system, designed to safely deliver anesthesia and monitor patients during MRI procedures.
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its 2022 second quarter financial results on July 29, 2022, before market opening. A conference call will be held on the same day at 11:00 a.m. Eastern Time to discuss the results and answer questions from investors. Interested parties can register for the call via the provided link. The company specializes in MRI-compatible medical devices, notably its MRidium® IV infusion pump and the 3880 vital signs monitoring system, designed to enhance patient safety during MRI procedures. More details can be found on their official website.
Perimeter Medical Imaging AI has appointed Chris Scott as the new Chief Financial Officer, effective immediately. Scott brings extensive experience in the medtech sector, having previously served as CFO at iRadimed Corporation (NASDAQ: IRMD) and successfully led them through an IPO, increasing their market cap from $10 million to $600 million. The company is well-positioned with a strong balance sheet and is focused on further developing its S-Series OCT and next-gen AI technology.
IRADIMED CORPORATION (NASDAQ:IRMD) has appointed John (Jack) Glenn as its new Chief Financial Officer, effective on or before June 20, 2022. With over 30 years of experience in corporate finance, Glenn's expertise includes roles at Esko Bionics and Sonendo, as well as a strong background in the medical device sector. The company, recognized for its innovative MRI-compatible medical devices, aims to leverage Glenn's strategic financial management to support its ongoing growth trajectory, as stated by CEO Roger Susi.
IRADIMED CORPORATION (NASDAQ: IRMD) reported strong first-quarter 2022 results with revenue of $12.3 million, a significant increase from $9.2 million in Q1 2021. GAAP diluted earnings per share (EPS) reached $0.20, while non-GAAP diluted EPS was $0.22. The company announced a full-year revenue guidance increase to $52.5 million to $53.2 million and non-GAAP EPS guidance of $0.96 to $1.03. Domestic sales accounted for 81.1% of total revenue, indicating strong market demand. A special dividend of $1.00 per share was also declared.
IRADIMED CORPORATION (NASDAQ: IRMD) announced the resignation of Chris Scott, the Chief Financial and Operating Officer, effective May 27, 2022. Scott has been with the company since December 2013 and is leaving to pursue other opportunities. Matt Garner, the Controller, will take on the role of interim CFO during the transition. CEO Roger Susi expressed gratitude for Scott's contributions over the years and confidence in Garner's ability to lead the finance department. A formal search for a new CFO is underway.
IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its 2022 Q1 financial results on April 29, 2022, before the market opens. A conference call will follow at 11:00 a.m. ET to discuss the results and address questions. Interested participants can dial in or join via the company’s website. IRADIMED specializes in MRI-compatible medical devices, including the MRidium® IV infusion pump and the 3880 vital signs monitoring system, both designed to enhance safety during MRI procedures.
IRADIMED CORPORATION (NASDAQ: IRMD) has announced a special cash dividend of $1.00 per share, payable on February 24, 2022, to shareholders of record by February 17, 2022. This decision reflects the company's strong financial performance, with a cash reserve of nearly $62 million at the end of 2021. The Board aims to return excess cash to its shareholders while ensuring operational and investment needs are met.
iRadimed Corporation (NASDAQ: IRMD) reported fourth-quarter 2021 revenue of $11.9 million, a 39% increase from the previous year, with net income at $3.9 million or $0.31 per diluted share. For the full year 2021, revenue reached $41.8 million, up 32%, with net income of $9.3 million or $0.74 per diluted share. The company anticipates revenue guidance for 2022 between $51.4 million and $52.2 million and GAAP EPS of $0.82 to $0.90, reflecting continued demand for its MRI-compatible devices despite supply chain challenges.
IRADIMED CORPORATION (NASDAQ: IRMD) will release its 2021 fourth quarter financial results before market opening on February 4, 2022. A conference call is scheduled for the same day at 11:00 a.m. ET to discuss these results and address questions. Interested parties can listen by dialing 1-844-413-1781 or 1-716-247-5767, entering reservation code 2899922. The call will also be streamed live online, with a recording available on the company's website for 90 days post-call.